|
1
|
Warnakulasuriya S: Global epidemiology of
oral and oropharyngeal cancer. Oral Oncol. 45:309–316. 2009.
View Article : Google Scholar
|
|
2
|
Shin KH and Kim RH: An updated review of
oral cancer stem cells and their stemness regulation. Crit Rev
Oncog. 23:189–200. 2018. View Article : Google Scholar
|
|
3
|
O'Brien CA, Kreso A and Jamieson CH:
Cancer stem cells and self-renewal. Clin Cancer Res. 16:3113–3120.
2010. View Article : Google Scholar
|
|
4
|
Lee CR, Lee SH, Rigas NK, Kim RH, Kang MK,
Park NH and Shin KH: Elevated expression of JMJD6 is associated
with oral carcinogenesis and maintains cancer stemness properties.
Carcinogenesis. 37:119–128. 2016. View Article : Google Scholar
|
|
5
|
Lee SH, Lee CR, Rigas NK, Kim RH, Kang MK,
Park NH and Shin KH: Human papillomavirus 16 (HPV16) enhances tumor
growth and cancer stemness of HPV-negative oral/oropharyngeal
squamous cell carcinoma cells via miR-181 regulation.
Papillomavirus Res. 1:116–125. 2015. View Article : Google Scholar
|
|
6
|
Lee SH, Rigas NK, Lee CR, Bang A, Srikanth
S, Gwack Y, Kang MK, Kim RH, Park NH and Shin KH: Orai1 promotes
tumor progression by enhancing cancer stemness via NFAT signaling
in oral/oropharyngeal squamous cell carcinoma. Oncotarget.
7:43239–43255. 2016. View Article : Google Scholar
|
|
7
|
Tamura T, Shomori K, Nakabayashi M, Fujii
N, Ryoke K and Ito H: Zoledronic acid, a third-generation
bisphosphonate, inhibits cellular growth and induces apoptosis in
oral carcinoma cell lines. Oncol Rep. 25:1139–1143. 2011.
View Article : Google Scholar
|
|
8
|
Martin CK, Werbeck JL, Thudi NK, Lanigan
LG, Wolfe TD, Toribio RE and Rosol TJ: Zoledronic acid reduces bone
loss and tumor growth in an orthotopic xenograft model of
osteolytic oral squamous cell carcinoma. Cancer Res. 70:8607–8616.
2010. View Article : Google Scholar
|
|
9
|
Okamoto S, Kawamura K, Li Q, Yamanaka M,
Yang S, Fukamachi T, Tada Y, Tatsumi K, Shimada H, Hiroshima K, et
al: Zoledronic acid produces antitumor effects on mesothelioma
through apoptosis and S-phase arrest in p53-independent and Ras
prenylation-independent manners. J Thorac Oncol. 7:873–882. 2012.
View Article : Google Scholar
|
|
10
|
Corey E, Brown LG, Quinn JE, Poot M,
Roudier MP, Higano CS and Vessella RL: Zoledronic acid exhibits
inhibitory effects on osteoblastic and osteolytic metastases of
prostate cancer. Clin Cancer Res. 9:295–306. 2003.
|
|
11
|
Jiang P, Zhang P, Mukthavaram R, Nomura N,
Pingle SC, Teng D, Chien S, Guo F and Kesari S: Anti-cancer effects
of nitrogen-containing bisphosphonates on human cancer cells.
Oncotarget. 7:57932–57942. 2016. View Article : Google Scholar
|
|
12
|
Sewing L, Steinberg F, Schmidt H and Göke
R: The bisphosphonate zoledronic acid inhibits the growth of
HCT-116 colon carcinoma cells and induces tumor cell apoptosis.
Apoptosis. 13:782–789. 2008. View Article : Google Scholar
|
|
13
|
Li Y, Du Y, Sun T, Xue H, Jin Z and Tian
J: PD-1 blockade in combination with zoledronic acid to enhance the
antitumor efficacy in the breast cancer mouse model. BMC Cancer.
18:6692018. View Article : Google Scholar
|
|
14
|
Vitellius C, Fizanne L, Menager-Tabourel
E, Nader J, Baize N, Laly M, Lermite E, Bertrais S and Caroli-Bosc
FX: The combination of everolimus and zoledronic acid increase the
efficacy of gemcitabine in a mouse model of pancreatic
adenocarcinoma. Oncotarget. 9:28069–28082. 2018. View Article : Google Scholar
|
|
15
|
Barrett-Lee P, Casbard A, Abraham J, Hood
K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R,
Griffiths G and Murray N: Oral ibandronic acid vs. intravenous
zoledronic acid in treatment of bone metastases from breast cancer:
A randomised, open label, non-inferiority phase 3 trial. Lancet
Oncol. 15:114–122. 2014. View Article : Google Scholar
|
|
16
|
Coleman R, Cameron D, Dodwell D, Bell R,
Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, et
al: Adjuvant zoledronic acid in patients with early breast cancer:
Final efficacy analysis of the AZURE (BIG 01/04) randomised
open-label phase 3 trial. Lancet Oncol. 15:997–1006. 2014.
View Article : Google Scholar
|
|
17
|
Lee SH, Hong HS, Liu ZX, Kim RH, Kang MK,
Park NH and Shin KH: TNFα enhances cancer stem cell-like phenotype
via Notch-Hes1 activation in oral squamous cell carcinoma cells.
Biochem Biophys Res Commun. 424:58–64. 2012. View Article : Google Scholar
|
|
18
|
Shin KH, Bae SD, Hong HS, Kim RH, Kang MK
and Park NH: miR-181a shows tumor suppressive effect against oral
squamous cell carcinoma cells by downregulating K-ras. Biochem
Biophys Res Commun. 404:896–902. 2011. View Article : Google Scholar
|
|
19
|
Yanamoto S, Kawasaki G, Yamada S,
Yoshitomi I, Kawano T, Yonezawa H, Rokutanda S, Naruse T and Umeda
M: Isolation and characterization of cancer stem-like side
population cells in human oral cancer cells. Oral Oncol.
47:855–860. 2011. View Article : Google Scholar
|
|
20
|
Zhang P, Zhang Y, Mao L, Zhang Z and Chen
W: Side population in oral squamous cell carcinoma possesses tumor
stem cell phenotypes. Cancer Lett. 277:227–234. 2009. View Article : Google Scholar
|
|
21
|
Baba T, Naka K, Morishita S, Komatsu N,
Hirao A and Mukaida N: MIP-1α/CCL3-mediated maintenance of
leukemia-initiating cells in the initiation process of chronic
myeloid leukemia. J Exp Med. 210:2661–2673. 2013. View Article : Google Scholar
|
|
22
|
Blanpain C, Buser R, Power CA, Edgerton M,
Buchanan C, Mack M, Simmons G, Clapham PR, Parmentier M and
Proudfoot AE: A chimeric MIP-1 alpha/RANTES protein demonstrates
the use of different regions of the RANTES protein to bind and
activate its receptors. J Leukocyte Biol. 69:977–985. 2001.
|
|
23
|
Schech AJ, Kazi AA, Gilani RA and Brodie
AH: Zoledronic acid reverses the epithelial-mesenchymal transition
and inhibits self-renewal of breast cancer cells through
inactivation of NF-κB. Mol Cancer Ther. 12:1356–1366. 2013.
View Article : Google Scholar
|
|
24
|
Buhler H, Hoberg C, Fakhrian K and
Adamietz IA: Zoledronic acid inhibits the motility of cancer
stem-like cells from the human breast cancer cell line MDA-MB 231.
In Vivo. 30:761–768. 2016. View Article : Google Scholar
|
|
25
|
Rouhrazi H, Turgan N and Oktem G:
Zoledronic acid overcomes chemoresistance by sensitizing cancer
stem cells to apoptosis. Biotech Histochem. 93:77–88. 2018.
View Article : Google Scholar
|
|
26
|
Kijima T, Koga F, Fujii Y, Yoshida S,
Tatokoro M and Kihara K: Zoledronic acid sensitizes renal cell
carcinoma cells to radiation by downregulating STAT1. PLoS One.
8:e646152013. View Article : Google Scholar
|
|
27
|
Silva TA, Ribeiro FL, Oliveira-Neto HH,
Watanabe S, Alencar Rde C, Fukada SY, Cunha FQ, Leles CR, Mendonça
EF and Batista AC: Dual role of CCL3/CCR1 in oral squamous cell
carcinoma: Implications in tumor metastasis and local host defense.
Oncol Rep. 18:1107–1113. 2007.
|
|
28
|
da Silva JM, Moreira Dos Santos TP, Sobral
LM, Queiroz-Junior CM, Rachid MA, Proudfoot AEI, Garlet GP, Batista
AC, Teixeira MM, Leopoldino AM, et al: Relevance of CCL3/CCR5 axis
in oral carcinogenesis. Oncotarget. 8:51024–51036. 2017. View Article : Google Scholar
|
|
29
|
Hsu CJ, Wu MH, Chen CY, Tsai CH, Hsu HC
and Tang CH: AMP-activated protein kinase activation mediates
CCL3-induced cell migration and matrix metalloproteinase-2
expression in human chondrosarcoma. Cell Commun Signal. 11:682013.
View Article : Google Scholar
|
|
30
|
Liao YY, Tsai HC, Chou PY, Wang SW, Chen
HT, Lin YM, Chiang IP, Chang TM, Hsu SK, Chou MC, et al: CCL3
promotes angiogenesis by dysregulation of miR-374b/ VEGF-A axis in
human osteosarcoma cells. Oncotarget. 7:4310–4325. 2016. View Article : Google Scholar
|
|
31
|
Kim JH, Kim WS, Hong JY, Ryu KJ, Kim SJ
and Park C: Epstein-Barr virus EBNA2 directs doxorubicin resistance
of B cell lymphoma through CCL3 and CCL4-mediated activation of
NF-kappaB and Btk. Oncotarget. 8:5361–5370. 2017. View Article : Google Scholar
|
|
32
|
Jin J, Colin P, Staropoli I,
Lima-Fernandes E, Ferret C, Demir A, Rogée S, Hartley O,
Randriamampita C, Scott MG, et al: Targeting spare CC chemokine
receptor 5 (CCR5) as a principle to inhibit HIV-1 entry. J Biol
Chem. 289:19042–19052. 2014. View Article : Google Scholar
|
|
33
|
Jiao X, Velasco-Velázquez MA, Wang M, Li
Z, Rui H, Peck AR, Korkola JE, Chen X, Xu S, DuHadaway JB, et al:
CCR5 governs DNA damage repair and breast cancer Stem cell
expansion. Cancer Res. 78:1657–1671. 2018. View Article : Google Scholar
|
|
34
|
Mencarelli A, Graziosi L, Renga B,
Cipriani S, D'Amore C, Francisci D, Bruno A, Baldelli F, Donini A
and Fiorucci S: CCR5 antagonism by maraviroc reduces the potential
for gastric cancer cell dissemination. Transl Oncol. 6:784–793.
2013. View Article : Google Scholar
|
|
35
|
Velasco-Velázquez M, Jiao X, De La Fuente
M, Pestell TG, Ertel A, Lisanti MP and Pestell RG: CCR5 antagonist
blocks metastasis of basal breast cancer cells. Cancer Res.
72:3839–3850. 2012. View Article : Google Scholar
|
|
36
|
Maehara O, Suda G, Natsuizaka M, Ohnishi
S, Komatsu Y, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, et al:
Fibroblast growth factor-2-mediated FGFR/Erk signaling supports
maintenance of cancer stem-like cells in esophageal squamous cell
carcinoma. Carcinogenesis. 38:1073–1083. 2017. View Article : Google Scholar
|
